We are live on ! Find out more
VEA

Virtus ETF Advisers Portfolio holdings

AUM $215M
1-Year Est. Return 53.68%
This Fund
S&P 500
This Quarter Est. Return
+25.81%
1 Year Est. Return
+53.68%
3 Year Est. Return
+121.72%
5 Year Est. Return
+144.54%
10 Year Est. Return
+633.35%
AUM
$241M
AUM Growth
+$50.3M
Cap. Flow
+$11.8M
Cap. Flow %
4.88%
Top 10 Hldgs %
9.37%
Holding
372
New
47
Increased
146
Reduced
160
Closed
17

Top Buys

Rank Stock Value
1
BEPC icon
Brookfield Renewable
BEPC
+$1.51M
2
WES icon
Western Midstream Partners
WES
+$926K
3
PSXP
PHILLIPS 66 PARTNERS LP
PSXP
+$707K
4
DK icon
Delek US
DK
+$681K
5
CVI icon
CVR Energy
CVI
+$669K

Top Sells

Rank Stock Value
1
IMMU
Immunomedics Inc
IMMU
+$1.61M
2
AIMT
Aimmune Therapeutics
AIMT
+$1.13M
3
AIV
Aimco
AIV
+$1.1M
4
VIV icon
Telefônica Brasil
VIV
+$1.01M
5
MNTA
Momenta Pharmaceuticals, Inc.
MNTA
+$988K

Sector Composition

Rank Sector Weight
1 Healthcare 29.53%
2 Real Estate 18.96%
3 Energy 16.61%
4 Materials 11.31%
5 Utilities 7.08%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CDXS icon
176
Codexis
CDXS
$136M
$342K 0.14%
+15,659
New +$258K
EIDX
177
DELISTED
Eidos Therapeutics, Inc. Common Stock
EIDX
$342K 0.14%
2,601
-4,144
-61% -$366K
IBRX icon
178
ImmunityBio
IBRX
$7.3B
$338K 0.14%
+25,388
New +$244K
MYOV
179
DELISTED
Myovant Sciences Ltd.
MYOV
$338K 0.14%
12,236
-6,088
-33% -$119K
EDIT icon
180
Editas Medicine
EDIT
$402M
$336K 0.14%
4,798
-6,619
-58% -$272K
ITOS
181
DELISTED
iTeos Therapeutics
ITOS
$335K 0.14%
+9,916
New +$263K
MAIN icon
182
Main Street Capital
MAIN
$5.14B
$334K 0.14%
10,341
-1,034
-9% -$31.8K
KOD icon
183
Kodiak Sciences
KOD
$2.52B
$333K 0.14%
2,268
-3,048
-57% -$340K
RGNX icon
184
Regenxbio
RGNX
$615M
$333K 0.14%
7,339
-1,420
-16% -$49.6K
BCSF icon
185
Bain Capital Specialty
BCSF
$833M
$330K 0.14%
27,202
-5,022
-16% -$55.7K
IMTX icon
186
Immatics
IMTX
$1.19B
$329K 0.14%
+30,508
New +$322K
PGEN icon
187
Precigen
PGEN
$1.97B
$326K 0.14%
+31,962
New +$207K
STOK icon
188
Stoke Therapeutics
STOK
$1.83B
$326K 0.14%
+5,264
New +$241K
APLS
189
DELISTED
Apellis Pharmaceuticals
APLS
$324K 0.13%
5,668
-4,279
-43% -$181K
NGM
190
DELISTED
NGM Biopharmaceuticals, Inc. Common Stock
NGM
$324K 0.13%
10,685
-4,195
-28% -$91.8K
TCRR
191
DELISTED
TCR2 Therapeutics Inc. Common Stock
TCRR
$324K 0.13%
+10,491
New +$265K
NSL
192
DELISTED
NUVEEN SENIOR INCM FD
NSL
$323K 0.13%
62,152
-8,488
-12% -$42.2K
ARNA
193
DELISTED
Arena Pharmaceuticals Inc
ARNA
$323K 0.13%
4,202
-832
-17% -$62.4K
ALXO icon
194
ALX Oncology
ALXO
$268M
$318K 0.13%
+3,688
New +$222K
KRTX
195
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
$317K 0.13%
3,122
-200
-6% -$18.5K
JRO
196
DELISTED
Nuveen Floating Rate Income Opportunty Fund
JRO
$317K 0.13%
36,603
-5,354
-13% -$44.6K
RIGL icon
197
Rigel Pharmaceuticals
RIGL
$712M
$316K 0.13%
9,036
-8,088
-47% -$234K
JFR icon
198
Nuveen Floating Rate Income Fund
JFR
$1.23B
$314K 0.13%
35,910
-5,015
-12% -$42.3K
DSU icon
199
BlackRock Debt Strategies Fund
DSU
$592M
$313K 0.13%
29,951
-1,570
-5% -$15.8K
RETA
200
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
$309K 0.13%
2,498
+605
+32% +$79.5K
6 7
8
9 10

Similar funds

NCM
NEXTBio Capital Management Menlo Park, California $215M AUM
SSA
SSA Swiss Advisors Zurich $216M AUM 17.86% 1-Year Est. Return
LIWM
Long Island Wealth Management Melville, New York $216M AUM 14.59% 1-Year Est. Return
VFG
V2 Financial group Naperville, Illinois $215M AUM 15.18% 1-Year Est. Return
IAM
Impala Asset Management Palm Beach, Florida $215M AUM 86.77% 1-Year Est. Return
1M
1248 Management Kansas City, Missouri $216M AUM 12.29% 1-Year Est. Return
GC
GatePass Capital Independence, Ohio $214M AUM 29.83% 1-Year Est. Return
RC
Roubaix Capital Denver, Colorado $214M AUM 32.43% 1-Year Est. Return

Virtus ETF Advisers's Q4 2020 Portfolio in Review

As of Q4 2020, Virtus ETF Advisers held 372 positions worth $241M, up 26% from $191M the previous quarter. Its ten largest holdings account for 9.4% of the portfolio.

Virtus ETF Advisers deployed $11.8M of net new capital in Q4 2020, opening 47 new positions and adding to 146 existing holdings. Its largest new stake was Harmony Biosciences: 14,899 shares worth $539K.

By sector, the portfolio is most concentrated in Healthcare at 30% of assets, down from 32% a quarter earlier, followed by Real Estate and Energy.

On the sell side, the largest reduction was Amicus Therapeutics, an estimated $572K trimmed.

  • Virtus ETF Advisers's largest Q4 2020 buy was Harmony Biosciences: 14,899 shares worth $539K.
  • Virtus ETF Advisers added most to Brookfield Renewable in Q4 2020, an estimated $1.51M increase.
  • Virtus ETF Advisers's biggest Q4 2020 reduction was Amicus Therapeutics, cutting an estimated $572K.
  • Virtus ETF Advisers fully exited Immunomedics Inc in Q4 2020, selling an estimated $1.61M.
  • Virtus ETF Advisers's ten largest holdings make up 9.4% of its $241M portfolio in Q4 2020.
  • Virtus ETF Advisers opened 47 new positions and closed 17 in Q4 2020.
  • Virtus ETF Advisers's portfolio value rose 26% quarter-over-quarter to $241M.

Based on Virtus ETF Advisers's 13F filing for Q4 2020, filed 12 Feb 2021.